ATE479760T1 - Universelles signalpeptid gas1 - Google Patents

Universelles signalpeptid gas1

Info

Publication number
ATE479760T1
ATE479760T1 AT05729650T AT05729650T ATE479760T1 AT E479760 T1 ATE479760 T1 AT E479760T1 AT 05729650 T AT05729650 T AT 05729650T AT 05729650 T AT05729650 T AT 05729650T AT E479760 T1 ATE479760 T1 AT E479760T1
Authority
AT
Austria
Prior art keywords
heavy chain
chain variable
variable domain
immunoglobulin heavy
domain polypeptide
Prior art date
Application number
AT05729650T
Other languages
English (en)
Inventor
Wildt Rudolph De
Original Assignee
Domantis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Domantis Ltd filed Critical Domantis Ltd
Application granted granted Critical
Publication of ATE479760T1 publication Critical patent/ATE479760T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • C12N15/625DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C07K14/395Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Saccharomyces
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241Tumor Necrosis Factors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • C12N15/1037Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/055Fusion polypeptide containing a localisation/targetting motif containing a signal for localisation to secretory granules (for exocytosis)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Gas Separation By Absorption (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
AT05729650T 2004-03-24 2005-03-24 Universelles signalpeptid gas1 ATE479760T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55576404P 2004-03-24 2004-03-24
PCT/GB2005/001180 WO2005093074A1 (en) 2004-03-24 2005-03-24 Gas1 universal leader

Publications (1)

Publication Number Publication Date
ATE479760T1 true ATE479760T1 (de) 2010-09-15

Family

ID=34963448

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05729650T ATE479760T1 (de) 2004-03-24 2005-03-24 Universelles signalpeptid gas1

Country Status (11)

Country Link
US (1) US7846721B2 (de)
EP (2) EP2172553A1 (de)
AT (1) ATE479760T1 (de)
CY (1) CY1111063T1 (de)
DE (1) DE602005023291D1 (de)
DK (1) DK1737962T3 (de)
ES (1) ES2351509T3 (de)
PL (1) PL1737962T3 (de)
PT (1) PT1737962E (de)
SI (1) SI1737962T1 (de)
WO (1) WO2005093074A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1841796A2 (de) 2004-12-02 2007-10-10 Domantis Limited Bispezifische domänen-antikörper gegen serum albumin und glp-1 oder pyy
CA2688434A1 (en) 2007-06-06 2008-12-11 Domantis Limited Polypeptides, antibody variable domains and antagonists
CN102307897B (zh) 2008-12-05 2016-01-20 葛兰素集团有限公司 选出蛋白酶抗性多肽的方法
US9534043B2 (en) 2009-02-19 2017-01-03 Glaxo Group Limited Anti-serum albumin binding variants
PE20120170A1 (es) 2009-02-19 2012-03-21 Glaxo Group Ltd Variantes de union a anti-albumina de suero mejoradas
EA022925B1 (ru) 2009-02-19 2016-03-31 Глаксо Груп Лимитед Улучшенные полипептиды, вариабельные домены антител и антагонисты против tnfr1
EP2453920A2 (de) 2009-07-16 2012-05-23 Glaxo Group Limited Antagonisten, verwendung und verfahren zur teilweisen tnfr1-hemmung
SG177601A1 (en) 2009-07-16 2012-02-28 Glaxo Group Ltd Improved anti-serum albumin binding single variable domains
EP2459593A2 (de) 2009-07-29 2012-06-06 Glaxo Group Limited Einzeldomänenantikörper gegen tgf-beta-rezeptor typ ii
WO2011086143A2 (en) 2010-01-14 2011-07-21 Glaxo Group Limited Liver targeting molecules
CA2796932A1 (en) 2010-04-21 2011-10-27 Glaxo Group Limited Binding domains
EP2571900A1 (de) 2010-05-20 2013-03-27 Glaxo Group Limited Verbesserte antiserumalbuminbindende varianten
EP2603607B1 (de) * 2010-08-11 2016-04-06 Celula, Inc. Dns genotypisierung
WO2012020143A1 (en) 2010-08-13 2012-02-16 Glaxo Group Limited Improved anti-serum albumin binding variants
EA201390116A1 (ru) 2010-08-20 2013-09-30 Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Улучшенные связывающие варианты против сывороточного альбумина
CA2823104A1 (en) 2011-01-06 2012-07-12 Glaxo Group Limited Ligands that bind tgf-beta receptor ii
EP2670778A1 (de) 2011-02-02 2013-12-11 Glaxo Group Limited Neuartige antigenbindende proteine
PL2699601T3 (pl) 2011-04-21 2018-05-30 Bristol-Myers Squibb Company Polipeptydy przeciwciała, które antagonizują CD40
ES2743401T3 (es) * 2012-07-05 2020-02-19 Hoffmann La Roche Sistema de expresión y secreción
EP3113796A1 (de) 2014-03-07 2017-01-11 Bristol-Myers Squibb Company Verfahren zur verwendung von antikörperpolypeptiden mit cd40-antagonisierung zur behandlung von entzündlichen darmerkrankungen

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9400600A (pt) * 1994-02-17 1995-10-24 Finep Financiadora De Estudos Processos para produção de uma protéina recombinante e/ou de glicosilfosfatidilinositol (GPI) em células de microorganismos eucariontes e para a obtenção de leveduras de S. cerevisae; célula de levedura sequência de nucleotídios; meio de cultura; medicamento ou vacina; e produto dos ditos processos
US6555310B1 (en) * 1997-04-04 2003-04-29 Biosite Diagnostics, Inc. Polyclonal libraries
US7094579B2 (en) * 2002-02-13 2006-08-22 Xoma Technology Ltd. Eukaryotic signal sequences for prokaryotic expression

Also Published As

Publication number Publication date
EP2172553A1 (de) 2010-04-07
DK1737962T3 (da) 2010-12-13
DE602005023291D1 (de) 2010-10-14
US7846721B2 (en) 2010-12-07
EP1737962A1 (de) 2007-01-03
CY1111063T1 (el) 2015-06-11
WO2005093074A1 (en) 2005-10-06
PT1737962E (pt) 2010-12-03
SI1737962T1 (sl) 2011-01-31
ES2351509T3 (es) 2011-02-07
PL1737962T3 (pl) 2011-02-28
US20070026462A1 (en) 2007-02-01
EP1737962B1 (de) 2010-09-01

Similar Documents

Publication Publication Date Title
CY1111063T1 (el) Καθολικος οδηγος gas1
DK1831362T3 (da) Syreaktive svampeproteaser
PT1523496E (pt) Produção de misturas de anticorpos de forma recombinante
NZ734307A (en) Antibodies specific for claudin 6 (cldn6)
EA200701443A1 (ru) Синтетические домены иммуноглобулина, обладающие свойствами связывания и сконструированные в участках молекулы, отличных от гипервариабельных участков
JP2014061000A5 (de)
DE60333793D1 (de) Feste oberfläche für biomolekülabgabe und assay mit hoher durchlaufleistung
WO2006116657A3 (en) Single-chain antibody with cleavable linker
WO2008005847A3 (en) Method of producing factor viii proteins by recombinant methods
ATE513907T1 (de) Polypeptide mit endoglucanase-aktivität und polynukleotide zu ihrer kodierung
ATE492633T1 (de) Polypeptide mit cellobiohydrolaseaktivität und dafür kodierende polynukleotide
ATE446972T1 (de) Il-1 bindende antikörper und fragmente davon
MX337991B (es) Metodo para detectar cancer.
DK1294876T3 (da) EV-VEGF-nukleinsyrer og -polypeptider samt fremgangsmåder til deres benyttelse
WO2009130459A3 (en) Epitopes of il-17a and il-17f and antibodies specific thereto
WO2009088924A3 (en) Methods and materials for targeted affinity enhancement
DK1609863T3 (da) Udskilte polypeptider og transmembranpolypeptider samt nucleinsyrer kodende for disse
ATE501266T1 (de) Verfahren zur fermentativen herstellung von antikörpern
WO2006053021A3 (en) Methods for engineering polypeptide variants via somatic hypermutation and polypeptides made thereby
DE60026733D1 (de) Histone-deacetylase-8 proteine, nukleinsäuren und methoden zur verwendung
DK2261327T3 (da) Nye enantioselektive mikrobielle nitrilhydrataser med bred substratspecificitet
ATE490320T1 (de) Verwendung von acetalen zur isolation von nukleinsäuren
ATE539163T1 (de) Auf der verwendung von mva beruhende impfstoffe
EP2377885A4 (de) Verfahren zur herstellung eines umfassenden anti-surface-antikörpers mit einem mittels proteinvernetzenden und fixierenden reagens fixierten mikroorganismus als antigen
WO2008008182A3 (en) Method of production of para-hydroxycinnamic acid

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1737962

Country of ref document: EP